digital imaging
Auto Added by WPeMatico
Data scientists: don’t be afraid to explore new avenues
I’m a native French data scientist who cut his teeth as a research engineer in computer vision in Japan and later in my home country. Yet I’m writing from an unlikely computer vision hub: Stuttgart, Germany.
But I’m not working on German car technology, as one would expect. Instead, I found an incredible opportunity mid-pandemic in one of the most unexpected places: An ecommerce-focused, AI-driven, image-editing startup in Stuttgart focused on automating the digital imaging process across all retail products.
My experience in Japan taught me the difficulty of moving to a foreign country for work. In Japan, having a point of entry with a professional network can often be necessary. However, Europe has an advantage here thanks to its many accessible cities. Cities like Paris, London, and Berlin often offer diverse job opportunities while being known as hubs for some specialties.
While there has been an uptick in fully remote jobs thanks to the pandemic, extending the scope of your job search will provide more opportunities that match your interest.
Search for value in unlikely places, like retail
I’m working at the technology spin-off of a luxury retailer, applying my expertise to product images. Approaching it from a data scientist’s point of view, I immediately recognized the value of a novel application for a very large and established industry like retail.
Europe has some of the most storied retail brands in the world — especially for apparel and footwear. That rich experience provides an opportunity to work with billions of products and trillions of dollars in revenue that imaging technology can be applied to. The advantage of retail companies is a constant flow of images to process that provides a playing ground to generate revenue and possibly make an AI company profitable.
Another potential avenue to explore are independent divisions typically within an R&D department. I found a significant number of AI startups working on a segment that isn’t profitable, simply due to the cost of research and the resulting revenue from very niche clients.
Companies with data are companies with revenue potential
I was particularly attracted to this startup because of the potential access to data. Data by itself is quite expensive and a number of companies end up working with a finite set. Look for companies that directly engage at the B2B or B2C level, especially retail or digital platforms that affect front-end user interface.
Leveraging such customer engagement data benefits everyone. You can apply it towards further research and development on other solutions within the category, and your company can then work with other verticals on solving their pain points.
It also means there’s massive potential for revenue gains the more cross-segments of an audience the brand affects. My advice is to look for companies with data already stored in a manageable system for easy access. Such a system will be beneficial for research and development.
The challenge is that many companies haven’t yet introduced such a system, or they don’t have someone with the skills to properly utilize it. If you finding a company isn’t willing to share deep insights during the courtship process or they haven’t implemented it, look at the opportunity to introduce such data-focused offerings.
In Europe, the best bets involve creating automation processes
I have a sweet spot for early-stage companies that give you the opportunity to create processes and core systems. The company I work for was still in its early days when I started, and it was working towards creating scalable technology for a specific industry. The questions that the team was tasked with solving were already being solved, but there were numerous processes that still had to be put into place to solve a myriad of other issues.
Our year-long efforts to automate bulk image editing taught me that as long as the AI you’re building learns to run independently across multiple variables simultaneously (multiple images and workflows), you’re developing a technology that does what established brands haven’t been able to do. In Europe, there are very few companies doing this and they are hungry for talent who can.
So don’t be afraid of a little culture shock and take the leap.
Powered by WPeMatico
Sony announces its first 5G flagship, the triple lens Xperia 1 II
Sony has announced its first 5G smartphone: The Xperia 1 II. (For the curious or confused, it is pronounced ‘Xperia One, Mark Two.’)
“No one understands the entertainment experience better than Sony,” said president of mobile communications, Mitsuya Kishida, claiming the company is “uniquely positioned” in the era of 5G cellular technology to offer its target users an “enriched” experience thanks to Sony’s extensive content portfolio.
“Whether you are a broadcast professional who requires dynamic speed or an everyday user who desires enhanced entertainment, Xperia with 5G takes your mobile experience to the next level,” he said.
As ever with Sony — a major b2b supplier of image sensors to other smartphone makers (rather than a major seller of its own phones) — it’s made the camera a huge focus for the new Android 10 flagship, which has a 6.5in 21:9 “CinemaWide” 4K HDR OLED (3840×1644) display and is powered by a Qualcomm 865 Snapdragon chip (with 8GB of RAM on board).
Round the back the Xperia 1 II packs three lenses which offer a selection of focal lengths (16mm, 24mm and 70mm) for capturing different types of photos — from super wide angle to portraits.
All three rear lenses have a 12MP sensor, while round the front there’s an 8MP lens. Sony is also using Zeiss optics for the first time in a smartphone, expanding a long-running collaboration to a new device type.
Talking up the camera, Kishida touted ultra-fast, low light autofocus, noting that it supports 20fps autofocus and auto-tracking burst (which he called a world first in a smartphone) for capturing crisp action shots.
“Our new continuous auto focus keeps tracking of moving subjects. What’s special about this is with 20fps it calculates the object 3x per frame — that’s 60x per second — capturing the very moment,” he said.
“With the power and speed of 5G you will be able to share those moments more quickly and more easily across the network,” he added.
Another photo-friendly feature is real-time eye auto focus. Sony demoed this by showing it working on a video of a cat playing with a toy. So, tl;dr: Sony has trained its model on data-sets of pets too, not just humans.
A ‘Photo Pro’ interface on the handset, meanwhile, has been designed to be familiar to users of Sony’s mirrorless Alpha cameras — letting photographers tune shots via access to tweakable parameters they’re used to using on Sony’s high end digital cameras.
Sony is paying the same mind to video makers, with a video editing interface on the device that offers features such as touch autofocus and custom white balance — which Kishida said will help “visual storytellers” control the camera more easily.
There’s also a noise reduction feature to improve audio capture.
Best of all, the Xperia 1II has a 3.5mm headphone jack — enabling audiophiles to enjoy the simple pleasure of plugging in their favorite pair of high-end wired headphones and tuning out everything else.
Kishida flagged the use of an AI technology, called DSEE Ultimate, which he said upscales the sound signal to “near high resolution audio” — including when streaming. “This the best on the go acoustic experience available,” he claimed.
On the games front he touted a collaboration that will let users of the device play a mobile optimized version of Call of Duty using PlayStation 4’s DualShock 4 wireless controller.
The handset, meanwhile, packs a 4,000mAh battery as well as fast wireless charging.
Per Kishida the Xperia 1 II will start shipping from Spring onwards, though it’s not yet clear which markets Sony will be bringing the device to. (Last year the company’s mobile division was reported to have defocused most of the global market in a bid to focus on profitability.)
The Xperia 1 II may have a fairly niche target buyer, as Sony is a relative bit player in consumer smartphone sales vs giants like Samsung and Huawei, but is intended to act as a showcase for what the company’s camera technologies can offer other mobile makers.
Sony’s mobile chief was making the announcements at a virtual press conference screened via YouTube after the company became one of the first big companies to pull out of attending the Mobile World Congress tradeshow.
MWC’s organizer, the GSMA, subsequently cancelled the annual mobile industry event, which had been due to take place in Barcelona this week, after scores of exhibitors said they would not attend due to public health concerns attached to the novel coronavirus.
MWC typically attracts more than 100,000 visitors across four days. So the sight of Sony’s press conference being streamed to an empty room — entirely devoid of cameras, claps or woos but still with built in pauses for the media to take photos of the new hardware — was more than a little surreal.
Kishida had another 5G handsets to tease: the Xperia Pro, a flagship handset aimed at video professionals. It features 5G mm wavelength technology for improved capability to stream high-resolution video, as well as a handy micro HDMI port for easy plugging in of other high end camera kit.
Sony touted tests it’s done with U.S. carrier Verizon (TechCrunch’s parent company) to use the forthcoming 5G handset for live streaming of live sports events.
“Sony’s expertise and long history in providing profession digital imaging solutions is very unique,” added Kishida. “Only Sony has such deep and well established relationships, and we are bringing decades of experience to an end-to-end solution — from professional content creation to mobile communications technology in 5G.”
There was a mid-range smartphone announcement, too, also shipping from Spring onwards: The Xperia 10 II packs a 6″ display and also features a triple lens camera as well as water resistance.
Powered by WPeMatico
Luna is a new kind of space company helping biotech find its footing in microgravity
Toronto-based startup Luna Design and Innovation is a prime example of the kind of space company that is increasingly starting up to take advantage of the changing economics of the larger industry. Founded by Andrea Yip, who is also Luna’s CEO, the bootstrapped venture is looking to blaze a trail for biotechnology companies who stand to gain a lot from the new opportunities in commercial space – even if they don’t know it yet.
“I’ve spent my entire career in the public and private health industry, doing a lot of product and service design and innovation,” Yip told me in an interview. “I was working in pharma[ceuticals] for several years, but at the end of 2017, I decided to leave the pharma world and I really wanted to find a way to work along the intersection of pharma, space and design, because I just believe that the future of health for humanity is in space.”
Yip founded Luna at the beginning of this year to help turn that belief into action, with a focus on highlighting the opportunities available to the biotechnology sector in making use of the research environment unique to space.
“We see space as a research platform, and we believe that it’s a research platform that can be leveraged in order to solve healthcare problems here on Earth,” Yip explained. “So for me, it was critically important to open up space to the biotech sector, and to the pharma sector, in order to use it as a research platform for R&D and novel discovery.”
The International Space Station has hosted a number of pharma and biotech experiments.
NASA’s work in space has led to a number of medical advances, inducing digital imaging tech used in breast biopsy, transmitters used for monitoring fetus development within the womb, LED’s used in brain cancer surgery and more. Work done on researching and developing pharmaceuticals in space is also something that companies including Merck, Proctor & Gamble and other industry heavyweights have been dabbling in for years, with experiments conducted on the International Space Station. Companies like SpaceFarma have now sent entire minilaboratories to the ISS to conduct research on behalf of clients. But it’s still a business with plenty of remaining under-utilized opportunity, according to Yip – and tons of potential.
“I think it’s a highly underutilized research platform, unfortunately, right now,” she said. “When it comes to certain physical and life sciences phenomena, we know that things behave differently in space, in what we refer to as microgravity-based environments […] We know that cancer cells, for instance, behave differently in short- and longer-term microgravity when it comes to the way that they metastasize. So being able to even acknowledge that type of insight, and try and understand ‘why’ can unlock a lot of new discovery and understanding about the way cancer actually functions […] and that can actually help us better design drugs, and treatment opportunities here on Earth, just based on those insights.”
Blue Origin’s New Shepard rocket. Credit: Blue Origin .
Yip says that while there has been some activity already in biotech and microgravity, “we’re on the early end of this innovation,” and goes on to suggest that over the course of the next ten or so years, the companies that will be disrupting the existing class of legacy big pharma players will be ones who’ve invested early and deeply in space-based research and development.
The role of Luna is to help biotech companies figure out how best to approach building out an investment in space-based research. To that end, one of its early accomplishments is securing a role as a ‘Channel Partner’ for Jeff Bezos’ commercial space launch company Blue Origin. This arrangement means that Luna acts a a sales partner for Blue Origin’s New Shepard suborbital rocket, working with potential clients for the Amazon founder’s rocket company on how and why they might seek to set up a sub-orbital space-based experiment.
That’s the near-term vision, and the way that Luna will seek to have the most impact here on Earth. But the possibilities of what the future holds for the biotech sector start to really open up once you consider the current trajectory of the space industry, including NASA’s next steps, and efforts by private companies like SpaceX to expand human presence to other planet.
“We’re talking about going back to the Moon by 2024,” Yip says, referring to NASA’s goal with its Artemis program. “We’re talking about going to Mars in the next few years. There’s a lot that we will need to uncover and discover for ourselves, and I think that’s a huge opportunity. Who knows what we’ll discover when we’re on other planets, and we’re actually putting people there? We have to start preparing for that and building capability for that.”
Powered by WPeMatico